FDA Advisory Committee Is Sign Of Grim Progress For Ferring’s Nocdurna
This article was originally published in The Pink Sheet Daily
Executive Summary
Ferring’s nocturia treatment seems headed for another rejection, but a chance to make its case at an advisory panel can be seen as a win for company’s 505(b)(2) desmopressin application.
You may also be interested in...
Desmopressin Battle: Ferring Asks FDA To Reject Serenity's Nocturia Drug
Serenity's SER120 should be held to the same efficacy standards as Ferring's Nocdurna, which the agency has declined to approve three times, citizen petition says.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.